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Abstract
O6-methylguanine-DNA methyltransferase (MGMT) is a DNA repair enzyme that protects cells 
from carcinogenic effects of alkylating agents; however, MGMT is silenced by promoter 
hypermethylation during carcinogenesis. A single nucleotide polymorphism (SNP) in an enhancer 
in the MGMT promoter was previously identified to be highly significantly associated with risk 
for MGMT methylation in lung cancer and sputum from smokers. To further genetic 
investigations, a genome-wide association and replication study was conducted in two smoker 
cohorts to identify novel loci for MGMT methylation in sputum that were independent of the 
MGMT enhancer polymorphism. Two novel trans-acting loci (15q15.2 and 17q24.3) that were 
identified acted together with the enhancer SNP to empower risk prediction for MGMT 
methylation. We found that the predisposition to MGMT methylation arising from the 15q15.2 
locus involved regulation of the ubiquitin protein ligase E3 component UBR1. UBR1 attenuation 
reduced turnover of MGMT protein and increased repair of O6-methylguanine in 
nitrosomethylurea-treated human bronchial epithelial cells (HBEC), while also reducing MGMT 
promoter activity and abolishing MGMT induction. Overall, our results substantiate reduced gene 
transcription as a major mechanism for predisposition to MGMT methylation in the lungs of 
smokers, and support the importance of UBR1 in regulating MGMT homeostasis and DNA repair 
of alkylated DNA adducts in cells.
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Introduction
O6-methylguanine-DNA methyltransferase (MGMT) is a DNA repair enzyme that protects 
cells from carcinogenic effects of alkylating agents by removing adducts from the O6 
position of guanine (1). This repair mechanism is conserved in all organisms and involves 
transfer of methyl and other alkyl groups from the O6 position of guanine in DNA to a 
cysteine residue within enzymatic active site of MGMT protein. The irreversible binding of 
the alkyl group to the MGMT protein functionally inactivates the enzyme and leads to a 
structural alteration resulting in the recognition by ubiquitin ligases and degradation by the 
proteasome (1,2). The recovery of MGMT activity after its inactivation with alkylating 
agents is slow and results entirely from de novo protein synthesis (3–5).
The predominant mechanism for MGMT gene inactivation in carcinogenesis is 
hypermethylation of a CpG island within its promoter–enhancer region that leads to 
transcriptional silencing in lymphoma and several solid tumors including brain, colon, lung, 
and head and neck cancers (6). Silencing of this gene is associated with an increased 
prevalence for G:C to A:T transition mutations in K-ras and p53 genes in colorectal and 
brain tumors respectively, consistent with the important role for this gene in removing the 
highly promutagenic adduct O6-methylguanine (O6MG) (7,8). Although alkylating adducts 
such as O6MG can be derived from endogenous methylation by S- adenosylmethionine, 
knockouts of MGMT failed to show enhanced tumor formation unless treated with 
exogenous alkylating carcinogens (9). MGMT methylation is a common event in lung 
adenocarcinomas and associated with tumor progression (10). Concomitant methylation of a 
panel of cancer-relevant genes including MGMT detected in lung epithelial cells present in 
sputum predicts risk for subsequent lung cancer incidence in moderate and heavy smokers 
(11,12). In addition, MGMT methylation is also a prognostic biomarker for response of 
glioblastoma patients to the alkylating agent temozolomide (13,14).
Genome-wide profiling of allele-specific methylation (ASM) using a methylation-sensitive 
SNP array identified >35,000 ASM sites across the genomes of multiple tissue types that 
were likely mediated by parental-origin (imprinting) or short distance cis-acting SNPs (15–
18). This effort was further expanded by running methylation quantitative trait loci 
(meQTL) analyses that associated genome-wide SNP array data with methylation array data 
to identify short and long distance cis- and trans- acting germline meQTL in normal tissues 
that included lung, adipose, peripheral blood lymphocyte, and brain (19–25). In normal lung, 
34,304 cis- and 585 trans- acting meQTL were identified and enriched in CTCF-binding 
sites, DNase I hypersensitivity regions, and histone marks (19). Four of five established lung 
cancer risk loci among persons with European ancestry are cis-acting meQTL (19). The 
findings of SNP/haplotype dependent ASM and meQTL contribute to understanding 
genetic-epigenetic interactions and also provide functional relevance for disease risk loci 
discovered from genome-wide association studies (GWAS).
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In addition to germline meQTL, somatic meQTL were also identified that affected the 
predisposition of cancer-relevant genes for promoter hypermethylation acquired in 
carcinogenesis for multiple tumor types (13,26–32). This is illustrated by our studies and 
others for MGMT methylation. An enhancer SNP rs16906252 located at the first exon-
intron boundary of MGMT was highly significantly associated with risk for MGMT 
methylation in colorectal cancer, pleural mesothelioma, lung adenocarcinoma, glioblastoma, 
and diffuse large B-cell lymphoma (13,27,29–32). Significant association was also seen for 
MGMT methylation in sputum from smokers (27). Functional characterization confirmed 
the ASM pattern in heterozygotes for rs16906252 with the 'A' allele preferentially silenced 
by methylation in primary lung tumors and lung cancer cell lines (27). Although rs16906252 
is a major determinant for acquisition of MGMT methylation in lung carcinogenesis, 20% of 
current and former smokers carrying wild homozygote (G/G) of rs16906252 are methylated 
for MGMT in their sputum (27), suggesting that other genetic or environmental factors may 
contribute to MGMT methylation. To address this issue, a GWAS discovery and replication 
study was conducted in two smoker cohorts from New Mexico to identify novel loci whose 
association with risk for MGMT methylation detected in sputum was independent of the 
enhancer SNP. Subsequent hypothesis-driven studies were designed based on the genetic 
associations detected to explore the underlying biological mechanisms.
Methods
Study Populations
Longitudinal cohorts that enrolled current and former smokers were used for the GWAS 
discovery (the Lovelace Smokers Cohort, LSC) and the replication (the Veterans Smokers 
Cohort, VSC). The LSC began recruitment of female smokers in 2001 and expanded to 
include male smokers in 2004. Enrollment is restricted to current and former smokers age 40 
to 74 y with a minimum of 15 pack-years of smoking. The VSC began recruitment of 
smokers in 2000 using enrollment criteria and procedures similar to the LSC. Most 
participants in the VSC are males with greater than 20 pack-years smoking history. In total, 
1675 lung cancer-free subjects (1200 subjects from LSC and 430 subjects from VSC) were 
included in this study. A detailed description of subject enrollment and follow has been 
provided previously (27). All samples were collected with informed consent. The study was 
approved by the Western Institutional Review Board and New Mexico VA Health Care 
System.
Sputum Collection and Measurement of MGMT Promoter Methylation
Induced and spontaneous morning sputum samples were collected in LSC and VSC, 
respectively. Sputum samples were washed multiple times using Saccomanno’s fixative 
prior to long-term storage at −80°C. Sputum adequacy defined as the presence of deep lung 
macrophages or Curschmann’s spiral (12) was assessed by cytotechnologists and subjects 
with cancer cells detected in sputum slides were removed from this study. Sputum DNA was 
isolated and bisulfite converted. Methylation status for CpGs around the transcriptional start 
site of MGMT was assessed using two stage methylation specific PCR (33). Methylation 
status was scored as 0 (unmethylated) or 1 (methylated). Our assay can reproducibly detect 
one methylated allele in a background of 10,000 unmethylated alleles (12).
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GWAS Genotyping and Quality Assurance
The HumanOmni2.5–4v1-H BeadChip (Illumina, San Diego, CA) was used to genotype 
2,450,000 SNPs in 1200 Caucasian smokers from the LSC. We removed 37 subjects due to 
low call rate (<95%, n=7), low heterozygosity (n=1), low Caucasian ancestry (<85%, n=2), 
and high relatedness with other samples (n=27). Furthermore, SNPs were excluded if they 
had a call rate of <90%, a minor allele frequency (MAF)<0.008, or p<10−8 for Hardy-
Weinberg equilibrium test, or were on Y or pseudo-autosomal region of X chromosomes. 
The MAF cutoff is a technical one to identify at least 20 heterozygotes for accurate genotype 
clustering required by GenomeStudio. After quality assessment, 1163 subjects with 
1,599,980 SNPs remained in the genetic association analysis (Supplementary Table 1). The 
genomic coordinate is based on hg18 unless mentioned otherwise.
SNP Selection for Replication
Four SNPs (rs72887860, rs62287262, rs16957091, and rs997781) associated with risk for 
MGMT methylation in LSC (p<10−5 in models with adjustment for rs16906252) and with 
MAF >0.1 were selected for replication using the VSC (n=430, Supplementary Table 2). 
Rs16957091 was genotyped as the tag SNPs at chromosome 15q15.2 locus for replication. 
These SNPs were genotyped using the TaqMan assay (Life Technologies, Carlsbad, CA) in 
the VSC.
Imputation of Chromosome 15
Imputation of chromosome 15 in the LSC was conducted using BEAGLE (version 3.3.2) 
with phased haplotype data of EUR populations (n for chromosomes = 758, 
EUR.chr15.phase1_release_v3.20101123) from 1000 Genomes project pilot 1 study as the 
reference panel. Masked analyses on 20% of SNPs on chromosome 15 identified a high 
correlation of the observed versus expected allelic frequencies (Pearson correlation 
coefficient = 0.98). The estimated allelic dosages for SNPs (n = 165,451) with dosage R2 ≥ 
0.3 and MAF ≥ 0.05 in the LSC and EUR reference populations were included for assessing 
genetic association with risk for gene methylation.
Enrichment of SNPs in ENCODE-annotated Regulatory Regions
The enrichment of SNPs in ENCODE-annotated regulatory regions within the 472-kb 
haplotype block at chromosome 15q15.2 locus was assessed using FunciSNP (34). Peak 
files included CCTC-binding factor (CTCF) binding sites, DNase I hypersensitivity 
locations, DNase digital genomic foot printing, and regions enriched in active (H3K4me3 
and H3K36me3) and repressive (H3K27me3) histone modification markers from small 
airway epithelial cells (SAEC). Known FAIRE-Seq (Formaldehyde-Assisted Isolation of 
Regulatory Elements), DNase I hypersensitivity location, and gene promoter were included 
as well.
Stable siRNA-mediated Knockdown of UBR1 in Human BEC lines
Stable UBR1 knock down (KD) cell lines were established using three immortalized human 
bronchial epithelial cell lines (HBEC1, HBEC4, and HBEC26) (35). The 
pSUPER.retro.puro (Oligo Engine, Seattle, WA) was modified to encode resistance to 
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hygromycin (pSUPER.retro.hyg). A pair of oligonucleotides were annealed and inserted into 




TCCGGG-3’). The resulting construct uses the H1 RNA promoter to express shRNAs that 
are converted by endogenous enzymes to siRNAs targeting UBR1 mRNA. These constructs 
were verified by sequencing and transfected in GP2–293 cells along with a plasmid 
encoding the VSV-G protein. The resultant pseudotyped retroviral particles were used to 
transduce HBECs and drug resistant cells or clones were obtained after selection with 
hygromycin. Control cells or clones were established following the same procedure except 
pSUPER.retro.hyg plasmid backbone was used. On average, 70–80% KD was achieved at 
the mRNA level in all HBECs. Western blots suggested that minimal residual UBR1 protein 
remained in KD HBECs compared to control lines (Figure 1a, not shown).
Promoter Activity Assays
A 1,528-bp fragment containing the entire promoter and CpG island of MGMT with 
different haplotype alleles was previously cloned into the pGL2-basic Luciferase Reporter 
Vector (Promega, Madison, WI) upstream of the luciferase coding sequence (27). Luciferase 
reporter constructs that contain HAP1 (wild haplotype allele) or HAP4 (haplotype allele 
carrying A allele of rs16906252) were transiently transfected in control HBEC4 and HBEC4 
with UBR1 KD using Lipofectamine 3000. Transfection in HBEC1 and HBEC26 was 
conducted using the Neon electroporation system. Cells were harvested 48 h post 
transfection and reporter activity was measured using the Dual Luciferase Assay System 
(Promega, Madison, WI).
Real Time PCR for Quantifying Gene Expression
RNA was isolated from primary human BEC cultures (n = 54), normal lungs (n = 6), and 
cell lines. TaqMan real-time PCR was conducted to quantify gene expression in cDNA 
using the delta threshold cycle method with β-actin as the endogenous control.
Western Blot and Protein Expression Quantification
Western blot was conducted to quantify protein levels of UBR1 and MGMT using 
antibodies from Abcam (anti-UBR1 antibody, ab42420) and Invitrogen (mouse anti-MGMT, 
35–7000). Protein extract (90 μg) was digested with 100 ng endoproteinase GluC in a 25 μl 
reaction mixture before being resolved in PAGE gels (36). Naïve and suicide MGMT 
protein levels were quantified by densitometry (Image Lab, Bio-Rad, Hercules, CA) of the 
individual bands.
Quantification of O6MG
HBECs were treated with 1mM nitrosomethylurea (MNU) in the dark for 30 min. Cells were 
harvested at 0, 24, 48, and 72 hr post MNU treatment. O6MG was quantified in genomic 
DNA using HPLC-MS (37). The average amount recovered for 50 fmol positive controls 
([15N5-13CD3]-O6-methyl-2’-deoxyguanosine) was 47±8 fmol (n=4). The limit of detection 
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was 1 fmol, while limit of quantitation was 2.5 fmol per injection. Genomic O6MG level 
was expressed as the ratio between the amount of O6MG and dG within each DNA sample. 
The percentage of O6MG left unrepaired at 24 hr post MNU treatment was further 
standardized by taking into account the cell growth rate.
The Cytokinesis-block Micronucleus (CBMN) Assay
Phytohemagglutinin (PHA) stimulated exponentially growing lymphocyte cultures 
established from LSC members (n=107) were treated with 1 mM MNU for 4 hr and then 
incubated with 4.5 µg/ml cytochalasin B for an additional 24 hr before harvest (38). The 
dose selected was within the linear dose-response range and caused obvious genotoxicity, 
but minimal cytotoxicity. The micronuclei and nucleoplasmic bridge were scored to allow 
the calculation of the percentage of cells with chromosomal damages.
Statistical analysis
In the GWAS discovery, the genetic association was assessed in 1163 subjects using logistic 
regression with adjustment for age and sex. The genotype of rs16906252 was further 
included for covariate adjustment in models that would identify novel SNPs whose 
association with risk for MGMT methylation was independent of rs16906252. SNPs were 
assessed under an additive genetic model. Odds ratio (OR) and 95% confidence intervals 
(95%CI) were calculated to quantify the magnitude of the association per allele.
In the VSC replication, logistic regression was applied to assess the association between 
each individual SNP and risk for MGMT methylation in 430 subjects with adjustment for 
age, ethnicity (Hispanic versus non-Hispanic White), and rs16906252. The inclusion of 
Hispanics (n=141) in the analysis is mainly due to the sample size consideration. However, 
the inclusion of both ethnicities should not affect our results because the prevalence of 
MGMT methylation and the distribution of the four SNPs are not different between the two 
major ethnicities in the VSC. Results from the two stages were combined by a meta-analysis 
using the inverse variance weighting method (39).
Generalized linear models (GLM) were used to assess the associations between SNPs under 
the additive inheritance model and gene expression (delta Ct relative to β-actin) in primary 
human BECs and normal lung tissues; between UBR1 KD status, promoter haplotype, and 
MGMT promoter activity in HBEC4; between UBR1 KD status and induction of MGMT 
expression upon MNU treatment; and between rs16857091 and log10 transformed 
percentage of cells with chromosomal damage. The GLM included design variables and 
variables associated with each of the outcomes (Supplementary Table 3). The paired t-test 
was used to compare the difference of the ratio of naïve versus suicide MGMT and O6MG 
between UBR1 KD and control cell lines. All statistical tests were two-sided. Statistical 
analyses were conducted in SAS 9.2, R 2.14, and PLINK 1.06.
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GWAS discovery in LSC
Comparison of the observed and expected distribution of association estimates calculated for 
the GWAS discovery indicated no evidence of population stratification (inflation 
factor=1.003, Supplementary Figure 1). GWAS discovery was conducted in 1163 LSC 
members with methylation of MGMT detected in 296 subjects (25.5%). Thirty-six common 
SNPs (MAF>0.1) were associated with risk for MGMT methylation with p<10−5 
(Supplementary Table 2). Enhancer SNP rs16906252 (not included on the HumanOmni2.5–
4v1-H BeadChip) previously shown to be highly significantly associated with risk for 
MGMT methylation was genotyped in the 1163 LSC members and the association clearly 
reached genome wide significance (p=4.3×10−31). SNP rs16906252 was included in the 
logistic regression model to allow for identification of novel SNPs with associations 
independent of rs16906252 and this identified 12 common SNPs with p<10−5 
(Supplementary Table 2). SNPs located around the MGMT promoter became non-
significant (ps>0.94, Supplementary Table 2 and Supplementary Figure 2), suggesting the 
associations seen for these SNPs reflected some degree of linkage disequilibrium (LD) with 
rs16906252. However, multiple associations around chromosome 15q15.2 locus remained 
statistically significant and thus likely independent of rs16906252.
Replication in VSC
Four SNPs (rs72887860, rs62287262, rs16957091, and rs997781) associated with risk for 
MGMT methylation in LSC with p<10−5 and MAF >0.1 were selected for replication in 430 
members from the Veteran Smokers cohort (VSC) with MGMT methylation detected in 107 
subjects (24.9%). Rs16957091 was genotyped as the tag SNP on chromosome 15q15.2. 
Associations were replicated on chromosome 15q15.2 (rs16957091, p=0.016) and 17q24.3 
loci (rs997781, p=0.016). Meta-analysis combining the results for these two SNPs from LSC 
and VSC identified associations of near genome-wide significance (Table 1). Data from the 
LSC and VSC cohorts were pooled to assess change in the area under the curve (AUC) of 
the receiver operating characteristic (ROC) by adding rs16957091, rs997781, and 
rs16906252 to the basic model containing age, sex, race, and cohort identifier only 
(Supplementary Table 4). Adding all three SNPs into model increased the ROC AUC by 
19.6% (from 54.2 to 73.8%, p=2.97×10−57).
Association based on imputed genotypes at chromosome 17q24.3 and 15q15.2 loci
Rs997781 is located within a 131-kb haplotype block (chr17:64593108–64724190, hg18) on 
chromosome 17q24.3 containing ABCA6 and ABCA10 (not shown). Rs16957091 is located 
within a 472-kb haplotype block (chr15:40709948–41181608, hg18) on chromosome 
15q15.2 that contains STARD9, CDAN1, TTBK2, and UBR1 (Figure 2). Genotype 
imputation successfully (dosage R2 ≥ 0.3) estimated the allelic dosage for 126,145 common 
SNPs (MAF≥0.05) on chromosome 15 that were not genotyped by the Illumina 
HumanOmni2.5M chip. Association analyses based on imputation results on chromosome 
15 identified five SNPs associated with risk for MGMT methylation with p-values slightly 
lower than that seen for rs16957091, although all five SNPs are in almost perfect LD with 
Leng et al. Page 7













rs16957091 (R2s≥0.95) (Figure 2). Imputation at chromosome 17q24.3 did not find any 
associations that were more significant than that seen for rs997781.
Rs16957091 affects UBR1 expression
The enrichment of SNPs in ENCODE-annotated regulatory regions within the 472-kb 
haplotype block (chr15:40709948–41181608, hg18) at chromosome 15q15.2 locus was 
assessed using FunciSNP with data from small airway epithelial cells (SAEC). Multiple 
chromatin features surrounding STARD9, CDAN1, TTBK2, and UBR1 were identified to 
overlap with SNPs in LD with rs16957091 (n=108, R2≥0.2, p-values by Benjamini-
Hochberg adjustment <0.01, Supplementary Figure 3). Thus, the effect of rs16957091 on the 
expression of these four genes was assessed in 54 human primary BEC cultures and 59 
normal lung tissues. Among the four genes within this block, UBR1 has the highest gene 
expression in human primary BECs (Figure 3a). A significant correlation of gene expression 
among UBR1, CDAN1, and TTBK2 was identified (pairwise Pearson correlation 
coefficients=0.46–0.67, ps≤0.0005). However, STARD9 expression was not correlated with 
the other three genes within the same haplotype block (ps>0.07) possibly due to genomic 
recombination detected within STARD9. A significant association was observed in human 
BECs (p for trend=0.018) and replicated in normal lung tissues (p for trend=0.018) with the 
variant allele (G) of rs16957091 associated with reduction in UBR1 gene expression (Figure 
3a). The effect of rs16957091 on STARD9, CDAN1, and TTBK2 gene expression was not 
statistically significant (ps>0.32).
Experiments were designed to exam whether rs16957091 – UBR1 expression correlation 
was caused by sequence-dependent allele specific gene expression. Nine SNPs were 
annotated to any UBR1 exons or 5’ or 3’ UTRs with MAF ranged from 0 to 0.12. LD 
analysis between rs16957091 and each of these nine SNPs using 1000 Genomes CEU 
population identified low LD between rs16957091 and rs3917223 (R2=0.34). The LD 
estimates between rs16957091 and each of the other eight SNPs are very low (R2=0–0.13). 
Sequencing genomic DNA and cDNA containing rs3917223 from seven BECs heterozygous 
for rs16957091 and rs3917223 did not identify an allele-specific gene expression pattern for 
rs3917223 .
Reduced UBR1 expression affects MGMT turnover and DNA repair
UBR1 contains binding sites recognizing internal degrons of MGMT protein and UBR1/
RAD6-dependent N-end rule pathway is a major mechanism targeting suicide MGMT 
protein by alkylating agents and also unmodified MGMT for subsequent degradation via the 
26S proteasome in eukaryotes (40,41). Recovery of MGMT activity after its inactivation 
results entirely from de novo protein synthesis (4). Our previous studies demonstrated 
reduced gene transcription associated with the enhancer SNP rs16906252 as a major 
mechanism predisposing MGMT for promoter hypermethylation in the lungs of smokers 
(27). Thus, the lower expression of UBR1 associated with rs16957091 variant allele could 
result in slower turnover of the MGMT protein under normal physiological conditions 
and/or following repair in response to challenge by the alkylating agents, that in turn may 
lead to reduced MGMT transcription.
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UBR1 stable KD cell lines were established from three immortalized HBECs (HBEC1, 
HBEC4, and HBEC26) to test this hypothesis. A protease V8 digestion method (36) was 
used to distinguish naïve and suicide MGMT in HBEC1 treated with different MNU 
concentrations (0, 0.5, 1, 2.5 mM) for 30 min. The ratio of naïve versus suicide MGMT 
decreased with increasing concentrations of MNU treatment with almost no active MGMT 
left at the highest MNU concentration (not shown). Interestingly, without MNU treatment, 
protease V8 cutting is still detected supporting formation of endogenous alkylating DNA 
adducts as a part of normal cellular metabolism in these cells (1,42), although the assay 
specificity for detecting suicide MGMT may not be perfect due to its potential binding to 
other proteins. The ratio of naïve versus suicide MGMT was higher in control HBECs 
compared to UBR1 KD lines (0.95 vs 0.71, paired ttest p=0.037, Figure 1b) with the largest 
difference seen in HBEC26 (0.36, Figure 1c), suggesting accumulation of suicide MGMT in 
UBR1 KD lines. UBR1 knockout cells are resistant to alkylating agent (MNNG) induced 
genotoxicity probably because UBR1 targets both alkylated and unmodified MGMT (41). 
Thus, HBECs were treated with 1mM MNU and O6MG was quantified in genomic DNA 
recovered from cells at 0, 24, 48, and 72 hr post MNU treatment. On average 78% of O6MG 
adducts were repaired within 24 hr in control HBECs. In contrast, 89% O6MG were 
repaired within 24 hr in UBR1 KD lines (Figure 1d). Rates of repair within 24 hr differed 
significantly between control and UBR1 KD (paired ttest p=0.011, Figure 1d). The modest 
but statistically significant effect of UBR1 KD on MGMT degradation and repair of O6-
methylguanine may reflect the complexity of constitutive and exogenous alkylating agent-
accelerated degradation of MGMT. In addition to the UBR1/RAD6-dependent N-end rule 
pathway, UFD4/UBC4-dependent ubiquitin fusion degradation pathway functions as an 
enhancer of the processivity of MGMT polyubiquitylation by N-end rule pathway through 
physical interaction between the HECT-type UFD4 E3 and the RING-type UBR1 E3 
(40,41).
Because rs16957091 reduced UBR1 expression and UBR1 KD was associated with faster 
DNA repair of O6MG induced by MNU, we further assessed whether rs16957091 is 
associated with better repair in cultured lymphocytes collected from LSC subjects (n=107). 
A significant inverse association (p=0.036, Figure 3b) between the number of rs16957091 G 
alleles and percentage of cells with chromosomal damage was observed, suggesting that the 
G allele associated with reduced UBR1 expression is associated with greater DNA repair of 
MNU-induced DNA damage.
UBR1 expression levels affect MGMT transcription
Reduced gene transcription is a major mechanism predisposing MGMT for promoter 
hypermethylation in multiple tissue types (13,27), therefore a luciferase reporter assay was 
used to assess whether UBR1 KD would result in reduced MGMT promoter activity. 
Consistent with our previous studies and others, HAP4 (rs16906252 carrier) was associated 
with a 35% (p<0.0001) and 22% (p=0.0019) reduction in promoter activity compared to 
HAP1 (wild type) in control and UBR1 KD HBEC1 lines, respectively (Figure 4a). 
Excitingly, UBR1 KD reduced HAP1 promoter activity by 25% compared to control line 
(p=0.0009). Reduction of promoter activity (12%) in UBR1 KD line was also observed for 
HAP4 (p=0.089) although to a lesser degree that likely stemmed from the inefficient 
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transcription regulatory mechanism due to carrying rs16906252. The combination of UBR1 
KD and HAP4 reduced promoter activity by 50% (p<0.0001) compared to wild type UBR1 
and HAP1. The reduction of HAP1 promoter activity in the UBR1 KD HBEC4 line was 
replicated in HBEC1 (reduced by 23%, p=0.0046) and HBEC26 (reduced by 28%, 
p=2.5×10−8) (Figure 4a). These findings suggest that impaired MGMT turnover due to 
UBR1 KD may lead to reduced MGMT transcription, an important factor in the 
predisposition for promoter hypermethylation of MGMT.
The recovery of MGMT activity after its inactivation by alkylating agent results entirely 
from de novo protein synthesis and this rate differs between pulmonary cell types in the rat 
(4,43). Furthermore, a large induction of MGMT measured in steady state RNA has been 
observed in rat liver cell lines >24 hr post alkylating agent treatment and was due to 
activation of the MGMT promoter (3,5). Strong induction of MGMT expression in steady 
state RNA was also observed in control HBEC4 and HBEC26 at 24 and 48 hr post MNU 
treatment (1mM), but not in control HBEC1 (Figure 4b). In contrast, only minimal induction 
was observed in HBEC4 and HBEC26 with UBR1 KD at 48 hr post MNU treatment (Figure 
4b). GLM was conducted to assess the effect of UBR1 status (KD vs. WT) and time point 
(24 hr vs 48 hr) on induction of MGMT expression in HBEC4 and HBEC26. MGMT 
induction at 24 and 48 hr post MNU treatment was not statistically different in either cell 
lines (ps>0.11). However, statistically significant differences were identified for MGMT 
induction between control and UBR1 KD in HBEC4 (least square means and standard error, 
1.68 ± 0.068 vs. 1.17 ± 0.068, p=0.0057) and HBEC26 (least square means and standard 
error, 1.43 ± 0.067 vs. 1.13 ± 0.067, p=0.032) in the GLM with adjustment for assay batch 
and time point (24 vs. 48 hr).
Discussion
Our GWAS study identified cis- and trans- acting SNPs that affect silencing of a DNA 
repair gene (MGMT) by promoter hypermethylation acquired during lung carcinogenesis. 
Two novel trans- acting loci at chromosome 15q15.2 and 17q24.3 were identified as being 
associated with risk for MGMT methylation detected in sputum and their effects were 
independent of the enhancer SNP rs16906252. These three SNPs together improved the 
ROC AUC by 20% in a logistic regression that explored determinants for risk for MGMT 
methylation in current and former smokers. Thus, SNPs affecting the predisposition of 
MGMT silencing by promoter hypermethylation, together with SNPs affecting methylation 
of other important cancer-relevant genes acquired during carcinogenesis may lead to the 
establishment of a polygenic marker that could improve current risk prediction models for 
these cancers (18).
MGMT methylation status is a validated prognostic biomarker for the response of 
glioblastoma patients to the alkylating agent temozolomide (14). Our previous study and 
others also suggested that MGMT methylation status may affect the response of lung tumors 
to temozolomide treatment (27,44). The assessment of MGMT promoter activity using 
HEBC4 identified a 50% reduction in luciferase reporter activity for the combination of 
UBR1 KD and HAP4 (rs16906252 carrier) compared to wild type UBR1 and HAP1 (non 
rs16906252 carrier). This functional assessment strongly supports the epidemiological 
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findings that subjects carrying variant alleles for cis- (rs16906252) and trans-(rs16957091) 
acting SNPs that regulate MGMT transcription had the highest risk for MGMT methylation 
(OR=17.9, 95%CI=10.7–30.1, p=5.8×10−28, Supplementary Table 5). Furthermore, these 
two SNPs should also augment MGMT methylation status for the better stratification of 
patients for alkylating therapy due to their association with reduced MGMT transcription in 
MGMT unmethylated cells.
The mechanism for trans- acting meQTL is largely unknown. Among 585 trans- acting 
meQTL identified in normal lungs, approximately 196 trans- acting meQTL were mediated 
by methylation levels of CpG sites nearby the trans- acting SNPs (19). Ontology 
classification of genes (n=115) in the region of the proximal CpG sites mediating the trans-
acting associations identified GTPase activity related genes, genes regulating transcription, 
and genetic imprinting as the top three categories involved in DNA methylation regulation. 
A unique mechanism underlying the predisposition of MGMT methylation in lungs of 
smokers involving the regulation of UBR1 expression by rs16957091 within the 
chromosome 15q15.2 locus was elucidated (Figure 5). Because reduced gene transcription is 
a major mechanism predisposing MGMT for promoter hypermethylation in multiple tissue 
types (13,27), three HBEC lines with stable UBR1 KD were established to assess whether 
reduced UBR1 expression could affect the MGMT transcription. The functional validity of 
UBR1 KD was confirmed by showing compromised degradation of suicide MGMT or 
unmodified MGMT and increased DNA repair towards MNU induced O6MG in UBR1 KD 
lines compared to control HBECs. These effects by UBR1 are consistent with its role of 
binding to the internal degrons of suicide MGMT protein and even unmodified MGMT for 
subsequent degradation via the 26S proteasome in eukaryotes (1,40,41). In addition, greater 
DNA repair towards O6MG in UBR1 KD lines may be due to the accumulation of 
unmodified MGMT resulting from UBR1 KD (41). More importantly, stable UBR1 KD 
reduced MGMT promoter activity and abolished the induction of MGMT expression in 
HBEC models treated with non-cytotoxic MNU. These findings suggest that compromised 
MGMT degradation may not be able to provide an efficient positive feedback to the MGMT 
transcriptional machinery under normal physiological conditions or in response to alkylating 
agent exposure. Thus, our findings not only substantiate the reduced gene transcription as a 
major determinant for MGMT methylation in the lungs of smokers, but also support the 
importance of UBR1 mediated N-end rule pathway in regulating MGMT homeostasis and 
DNA repair towards alkylated DNA adducts.
The mechanism for how rs16957091, located 223kb from UBR1 regulates its expression 
was explored by assessing the enrichment of rs16957091 and SNPs in moderate and high 
LD with it (R2≥0.2) in ENCODE-annotated regulatory regions surrounding UBR1 using 
SAEC data. Multiple chromatin features surrounding UBR1 were identified to overlap with 
SNPs (n=22) in LD with rs16957091 (Supplementary Figure 3), suggesting that a 
combination of variant alleles of these SNPs may form a genomic backbone associated with 
a particular active or repressive chromatin conformation that affects UBR1 expression. In 
addition, SNP rs68062403 located at +178 relative to the transcription start site of UBR1 is 
in moderate LD (R2=0.25) with rs16957091. A search of the ChIP-seq database identified 
multiple transcription factors (POLR2A, YY1, and TAF1) overlapping with the region 
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where rs68062403 resides in A549, a lung carcinoma cell line. Furthermore, rs68062403 is 
located within an open chromatin region likely to be enriched in gene regulatory elements in 
SAEC (Supplementary Figure 3) and A549 (not shown). Thus, the association seen in this 
study could be due to the LD with SNP rs68062403 that in turn may affect the binding of a 
transcription factor.
Our studies provide a proof-of-concept for a unique mechanism underlying the 
predisposition of MGMT methylation in lungs of smokers that involves the regulation of 
MGMT homeostasis by UBR1/RAD6 mediated N-end rule pathway (Figure 5). The cis- and 
trans- acting SNPs affecting MGMT methylation should have strong clinical translational 
significance in terms of their utility in cancer risk assessment and patient stratification for 
alkylating agent chemotherapy.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Effect of UBR1 KD on MGMT turnover and DNA repair. (a) Western blot for UBR1 KD in 
HBEC1. Stable transfection with pSUPER.retro.hyg expressing siRNA targeting UBR1 led 
to almost undetectable UBR1 protein in HBEC1; (b) The ratios of naïve versus suicide 
MGMT were higher in control HBECs compared to UBR1 KD lines (0.95±0.29 vs 
0.71±0.30, paired ttest p=0.037) with largest difference seen in HBEC26 (0.36); (c) Western 
blot for MGMT protein in control HBEC26 and UBR1 KD line with and without GluC 
digest; (d) DNA repair for O6MG is slower in control HBECs than UBR1 KD lines 
(percentage of O6MG left unrepaired at 24 hr post MNU treatment, 0.22±0.0049 vs. 
0.11±0.02, paired t-test p=0.011). Results are summarized with mean and standard deviation 
based on experiments from three HBEC lines.
Leng et al. Page 16














Imputation of chromosome 15q15.2. Imputation was conducted using phased genotype data 
of EUR populations from 1000 Genomes project. Genetic associations are plotted for 941 
variants (MAF≥0.05) within the region of Chr15: 40304748 – 41304718 (hg18) that include 
758 imputed variants (dosage R2 is ≥ 0.3). Circles are genotyped SNPs. Squares are imputed 
SNPs. The purple circle is for rs16957091. Degree of LD with rs16957091 is schemed as the 
gradient of red to dark blue color with red as high LD (R2=0.8–1) and blue as low LD 
(R2=0–0.2). No SNPs in LD (R2>0.2) with rs16957091 can be detected outside of this 
region on chromosome 15.
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Rs16957091 affects expression of UBR1 and DNA repair capacity towards MNU treatment. 
(a) G allele of rs16957091 is associated with reduced gene expression of UBR1 in primary 
human BECs (n=54, p=0.018) and normal lungs (n=59, p=0.018). Y axis was truncated 
between 0.0075 and 0.015. (b) G allele of rs16957091 is associated with lower percentage of 
cells with chromosomal damage (n=107, p=0.036), indicating better repair towards MNU 
treatment. Results are summarized with mean and standard error.
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Effect of UBR1 KD on MGMT promoter activity and induction of MGMT expression 
following MNU treatment. (a) Both UBR1 KD and HAP4 (rs16906252 carrier) reduced 
MGMT promoter activity in HBEC4. The combination of UBR1 KD and HAP4 reduced 
promoter activity by almost 50% (p<0.0001) compared to wild type UBR1 and HAP1. The 
reduction of HAP1 promoter activity in UBR1 KD HBEC4 lines was replicated in HBEC1 
(reduced by 23%, p=0.0046) and in HBEC26 (reduced by 28%, p=2.5×10−8). (b) MNU 
treatment at a non-cytotoxic dose (1mM) induced MGMT transcription in control HBEC4 
and HBEC26 at 24 and 48 hr post MNU treatment. UBR1 KD largely abolished this 
induction in HBEC4 and HBEC26. Although no induction was observed in HBEC1, control 
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line still had higher MGMT expression than UBR1 KD line (p=0.086). Results are 
summarized with mean and standard deviation.
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Conceptual diagram for cis- and trans- acting SNPs for MGMT promoter hypermethylation. 
UBR1/RAD6 mediated N-end rule pathway regulates MGMT homeostasis under normal 
MGMT turnover and degradation of suicide MGMT upon alkylating agent challenge. 
Reduced UBR1 expression due to SNPs at 15q15.2 locus likely induces the accumulation of 
unmodified MGMT that is associated with better DNA repair towards alkylating agent 
induced DNA adducts. In addition, the compromised degradation of unmodified MGMT and 
suicide MGMT is associated with reduced MGMT promoter activity and expression 
induction, although the molecular mechanism is still unknown. This study also verified 
MGMT enhancer SNP (rs16906252) as the driver cis- acting SNP for MGMT methylation 
through reducing MGMT transcription. Thus, both cis- and trans- acting SNPs could affect 
the MGMT transcriptional machinery that predisposes MGMT for promoter 
hypermethylation in lungs of smokers.
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